Compare FMY & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMY | ECOR |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | US |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 52.4M |
| IPO Year | N/A | 2018 |
| Metric | FMY | ECOR |
|---|---|---|
| Price | $12.12 | $6.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 3.6K | ★ 60.6K |
| Earning Date | 01-01-0001 | 04-11-2026 |
| Dividend Yield | ★ 6.98% | N/A |
| EPS Growth | N/A | ★ 53.51 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,182,000.00 |
| Revenue This Year | N/A | $28.92 |
| Revenue Next Year | N/A | $32.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 57.09 |
| 52 Week Low | $11.65 | $4.16 |
| 52 Week High | $12.39 | $19.49 |
| Indicator | FMY | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 52.07 |
| Support Level | $12.06 | $5.15 |
| Resistance Level | $12.18 | $6.89 |
| Average True Range (ATR) | 0.08 | 0.61 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 66.67 | 43.85 |
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.